Suspected Angioedema of Abdominal Viscera
- C. Guy;
- P. Cathebras; and
- H. Rousset
- Hopital Bellevue, Centre Hospitalier Universitaire, 42055 Saint-Etienne, France. Hopital Nord, Centre Hospitalier Universitaire, 42055 Saint-Etienne, France.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Angioedema caused by angiotensin-converting enzyme inhibitors is an unpredictable adverse event with potentially life-threatening consequences. The reported incidence of angiotensin-converting enzyme inhibitor-related angioedema is about 0.1% to 0.5% [1, 2]. Although angioedema usually occurs within 1 week after the drug is started, it has been reported in some patients after several months of therapy [3]. Angioedema usually involves the face, lips, and tongue but may also include the hands, feet, and genitalia, as well as the mucous membranes of the mouth and upper respiratory and gastrointestinal tracts [2]. Matsumura and colleagues [4] described a patient with abdominal visceral edema probably related to captopril. We report a new case associated with lisinopril.
A 29-year-old woman was treated for hypertension with lisinopril (20 mg/d) and hydrochlorothiazide (12.5 mg/d) since February 1993. She experienced two episodes of peritoneal effusion in June and December 1993, respectively. Each episode began with severe abdominal pain and swelling. She had no diarrhea, vomiting, or fever. Coelioscopic surgery done during the first episode showed ascites. Peritoneal fluid was a sterile inflammatory exudate with 85% lymphocytes (1500 G/L). Her genitourinary system was normal, and no definite diagnosis was made. During the second episode, an abdominal echogram showed a peritoneal effusion in the rectovaginal cul-de-sac. These two episodes resolved spontaneously, but the patient reported continuous bloating sensations. She was eventually hospitalized for a third episode of acute abdominal pain and swelling in January 1994. Routine biological measurements were normal. Hereditary angioedema was excluded on the basis of normal complement and complement 1-esterase inactivator levels. An abdominal echogram was normal. The patient had no history of idiopathic angioedema. Abdominal visceral angioedema caused by angiotensin-converting enzyme inhibitors was nevertheless suspected, and therapy with lisinopril was discontinued. The patient had no further episodes of abdominal pain during 6 months of follow-up.
Patients with hereditary or acquired deficiency of complement 1-esterase inactivator (angioneurotic edema) may present with acute abdominal pain and ascites [5]. Because angioedema induced by angiotensin-converting enzyme inhibitors shares clinical and pathophysiologic features with hereditary angioneurotic edema [2], and because acute abdominal pain probably related to these inhibitors has been reported [4], we believe that drug-induced visceral angioedema should be considered in cases of unexplained abdominal pain in patients receiving the inhibitors.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
RSS Feeds









